Introduction {#s0001}
============

An outbreak of respiratory disease caused by a novel coronavirus has now been labeled a pandemic by the World Health Organization (WHO). The disease is now formally known as coronavirus disease 2019 (COVID-19). COVID-19 is responsible for the death of about 322,000 people worldwide as of May 19, 2020 (Dong et al., [@CIT0023]). COVID-19 virus is a positive-stranded RNA virus with a crown-like appearance under an electron microscope (Fehr & Perlman, [@CIT0027]). The spike glycoproteins on the envelope of the virus cause this crown-like appearance. Other coronaviruses, such as the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), have similar structures with crown-like appearance. When the COVID-19 virus infects a cell, two replicase polyproteins, pp1a and pp1ab are synthesized by the RNA genome (Ziebuhr & Siddell, [@CIT0070]). These polyproteins include a replication/transcription complex, several structural proteins and two proteases. One of these proteases is the main protease of coronavirus (Mpro) which cuts the polyproteins into individual functional pieces that is responsible for the replication of new viruses (Thiel et al., [@CIT0056]; Ziebuhr et al., 1997). The Mpro has been identified as an attractive target for anti-coronavirus drugs (Al-Khafaji et al., [@CIT0004]; R. J. Khan et al., [@CIT0037]; S. A. Khan et al., [@CIT0037]) since it mediates viral replication and transcription (Dougherty & Semler, [@CIT0025]; Thiel et al., [@CIT0056]; Xue et al., [@CIT0064]; Yang et al., [@CIT0066]). Finding suitable inhibitors of the main protease can prevent the COVID-19 virus from multiplying in the host cell.

In addition to the main protease, coronaviruses contain at least three viral proteins, a spike glycoprotein (S), membrane protein (M), and envelope protein (E) (Belouzard et al., [@CIT0010]; Boopathi et al., [@CIT0012]). E and M proteins have been found to be important in viral assembly, trafficking, and release of viral-like particles, (Ruch & Machamer, [@CIT0050]; Siu et al., [@CIT0054]) while coronaviruses rely on the S protein to mediate virus entry into the host cell (Belouzard et al., [@CIT0010]; Bosch et al., [@CIT0013]). The novel coronavirus uses the S protein to bind to the human receptor containing angiotensin-converting enzyme 2 (ACE2) cells (Hoffmann et al., [@CIT0034]; Wrapp et al., [@CIT0063]) and uses the serine protease, TMPRSS2 (transmembrane protease serine 2), for S protein priming. Multiple studies have shown that COVID-19 has a higher affinity to ACE2, (Tian et al., [@CIT0057]; Wan et al., [@CIT0060]; Wrapp et al., [@CIT0063]), which may help to explain why COVID-19 has been more infectious.

Some antiviral drugs have been successfully developed to treat patients who are infected with HIV/AIDS and hepatitis C viruses. Most of these drugs are developed after successfully finding the protease inhibitor compounds that work by stopping the activity of protease enzymes; therefore, preventing the viruses from multiplying. Currently, there are over 16 protease inhibitors approved by the FDA to treat both HIV/AIDS and hepatitis C (Scholar, [@CIT0053]). A number of initial treatments for COVID-19 have included giving those infected the HIV protease inhibitors lopinavir and ritonavir, (Chu et al., [@CIT0019]) as well as Ebola antivirals (Hendaus, [@CIT0032]; Routh, [@CIT0049]).

Due to the importance of the coronavirus main protease (Mpro) in viral replication, our study utilized the crystal structure of 6LU7 (Liu et al., [@CIT0044]) from the PDB, (Berman et al., [@CIT0011]) which is the 312 amino acid main protease of the novel COVID-19 that is responsible for viral replication. The 6LU7 X-ray crystal structure is one of the first deposited main protease structures of the novel COVID-19 and this protein is a potential target for the inhibition of COVID-19. Protease inhibitors are compounds that block the action of proteases and can be used as antiviral drugs. A novel approach has been devised to identify the best five inhibitors from 2692 possible protease inhibitor compounds, that are known to bind to different proteases and their PDB (Berman et al., [@CIT0011]) structures are known, against the COVID-19 main protease.

Firstly, molecular docking studies were carried out on all 2692 protease inhibitor compounds to obtain the binding affinity of these compounds against the COVID-19 main protease. Then, 10 best inhibitor-protease complex systems obtained from docking were selected for further study with molecular dynamics (MD) simulations. Each MD simulations was carried out for 100 ns in solution with proper physiological conditions. Some inhibitors were found to leave the protease; therefore, these inhibitors are removed from further study. For the remaining inhibitor-protease systems, molecular docking calculations were again performed to understand the binding affinity of these inhibitor compounds against the protease derived from MD simulation. In our approach, the best inhibitors are chosen when inhibitor compounds are found to have high binding affinity in both stand-alone docking studies using the PDB structure and the structure obtained from MD simulation in solution. MD simulations of the inhibitor-protease systems were also used to further study the stability, structure and dynamics of these systems. We propose possible protease inhibitor compounds that can be investigated further with experiments for the development of an antiviral drug against COVID-19.

Methods {#s0002}
=======

The SDF files for 2692 protease inhibitor compounds were downloaded from the Protein Data Bank (PDB) (Berman et al., [@CIT0011]) to use in molecular docking. All 2692 compounds were uploaded into the virtual screening program PyRx (Dallakyan & Olson, [@CIT0022]). Hydrogen atoms were added and Gasteiger charges were computed (Gasteiger & Marsili, [@CIT0029]). All compounds were minimized using the UFF force field with the conjugate gradient algorithm for 200 steps (Rappé et al., [@CIT0048]). Molecular docking was performed with AutoDoc Vina (Trott & Olson, [@CIT0058]) to predict the binding affinity and the best binding mode of each of the 2692 protease inhibitors. AutoDoc Vina uses a hybrid scoring function that is inspired by X-score (Wang et al., [@CIT0061]), which accounts for van der waals forces, hydrogen bonding, deformation penalty, and hydrophobic effect. In addition, AutoDoc Vina combines both the conformational preferences of the receptor--ligand complex and experimental affinity measurements to compute its binding energy (Trott & Olson, [@CIT0058]). To perform molecular docking, the grid box was centered on the 6LU7 crystal structure and grid dimensions were set to 51.3737 × 66.9738 × 59.60 Å^3^ to cover the entirety of the protein. All other AutoDoc Vina parameters were left as default. MD simulations were performed using the AMBER 18 package (Case et al., [@CIT0016]). 11 systems made of COVID-19 main protease and potential inhibitors (Pubchem IDs: 118098670, 104161460, 137349331, 44228999, 163632044, 656932, 5289412, 90176081, 25141820 and PDB chemical ID: 10Q and N3) were prepared using the CHARMM36 additive force field (Brooks et al., [@CIT0015]; Lee et al., 2016) for proteins and CHARMM General Force Filed (CGenFF)(Vanommeslaeghe et al., [@CIT0059]) for ligands. The systems were solvated with TIP3P water molecules and the waterbox size was fit to the size of the protein complex within a radius of 10 Å from the surface of the complex. To mimic physiological conditions, 0.15 M KCl ions were added to the systems using the Monte-Carlo ion placing method. A steepest decent energy minimization was carried out for 2500 cycles and then the conjugate gradient algorithm was used for 5000 cycles. Next, the systems were equilibrated for 2 ns under (canonical ensemble) NVT conditions where amount of substance (N), volume (V), and temperature (T) are conserved. The temperature of 303.15 K was controlled using Langevin dynamics (Adelman & Doll, [@CIT0001]). A restraint constant of 1 kcal/mol was used to restrain the complexes in equilibration. After minimization and equilibration of the systems were conducted, long MD simulations of 100 ns were performed. Long MD simulations were performed under NPT conditions where the temperature was kept at 303.15 K and pressure at 1 atm to mimic experimental conditions. A friction coefficient, γ, of 1.0 ps^−1^ was used for the Langevin thermostat and the pressure was held constant with the Monte Carlo barostat. Integration was done using a leap-frog algorithm with a 2-fs time step. All bonds involving hydrogen atoms were constrained to their equilibrium values using SHAKE (Axelsen & Li, [@CIT0007]).

ProTox-II (Banerjee et al., [@CIT0008]) (<http://tox.charite.de/protox_II/index.php?site=home>) was used to predict the hepatotoxicity of five main inhibitors found in this study. ProTox-II predicts toxicity based on the compound's structure using molecular similarity, fragment propensity, machine learning, pharmacophores and is trained on real data to compute the toxic potential of virtual and existing compounds (Banerjee et al., [@CIT0008]).

Results and discussion {#s0003}
======================

From stand-alone docking calculations of 2692 inhibitors, the ten highest binding affinity inhibitors are presented in [Table 1](#t0001){ref-type="table"}. The highest binding affinity inhibitor is found to be a macrocyclic tissue factor--factor VIIa inhibitor (PubChem ID: 118098670), which has a binding affinity of −10.6 kcal/mol. The binding affinity of the inhibitor 118098670 to the protease structure obtained from the MD simulation of inhibitor-protease complex was also found to have the highest binding affinity, −10.0 kcal/mol. A complex between factor VIIa (FVIIa) proteases and its tissue factor (TF) trigger blood coagulation. Within the TF-FVIIa pathway exits a trypsin-like serine protease factor Xa. The identified macrocyclic tissue factor--factor VIIa inhibitor works by binding to the active site of factor Xa. Factor Xa and its pathway inhibitor complex cause a feedback inhibition of TF-FVIIa, preventing the coagulation of blood. Therefore, TF-FVIIa inhibitors are thought to be promising compounds for treating many thrombotic diseases due to their anticoagulation properties (Al-Horani & Desai, [@CIT0002]; Ladziata et al., [@CIT0041]; Lazarus et al., [@CIT0042]).

###### 

Binding affinity of inhibitors with COVID-19 main protease using molecular docking approach and the structures obtained from X-ray crystallography and 100 ns MD simulation.

  PubChem ID   IUPAC name                                                                                                                                                                                                                                                                                               Binding affinity using PDB structure (kcal/mol)   Binding affinity using MD structure (kcal/mol)
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------
  118098670    (2*R*,15*R*)-2-\[(1-Aminoisoquinolin-6-yl)amino\]-4,15,17-trimethyl- 7-\[1-(2*H*-tetrazol-5-yl)cyclopropyl\]-13-oxa-4,11-diazatricyclo \[14.2.2.16,10\]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione                                                                                                −10.6                                             −10.0
  104161460    (*R*)-6-(2″-((3-hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3- (5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)- 5,6-dihydro-1*H*-pyrazolo\[3,4-c\]pyridin-7(4*H*)-one                                                                                                           −10.2                                             −9.4
  5289412      *N*-\[(5*S*,9*S*,10*S*,13*S*)-9-Hydroxy-5,10-bis(2-methylpropyl)-4,7,12,16- tetraoxo-3,6,11,17-tetrazabicyclo\[17.3.1\]tricosa-1(22),19(23), 20-trien-13-yl\]-3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanamide                                                                                     −9.4                                              −9.7
  137349331    \[(2′*S*,5*R*,8*S*,10*R*,14*S*)-2′-ethenyl-26-fluoro-14-\[\[(3S)-1-methyl- 2-oxopiperidine-3-carbonyl\]amino\]-2,2,4,7,13-pentaoxospiro\[2lambda6 -thia-3,6,12,22-tetrazatricyclo\[21.4.0.08,12\]heptacosa-1(23),24,26-triene-5, 1′-cyclopropane\]-10-yl\] 4-fluoro-1,3-dihydroisoindole-2-carboxylate   −10.0                                             −9.3
  44228999     2-\[6-\[3-\[3-(aminomethyl)phenyl\]phenoxy\]-4-\[(3*R*)-3-(dimethylamino) pyrrolidin-1-yl\]-3,5-difluoropyridin-2-yl\]oxy-4-(dimethylamino)benzoic acid                                                                                                                                                  −9.8                                              --
  163632044    6-\[3-(\[1,3\]oxazolo\[4,5-B\]pyridin-2-Yl)-2-(Trifluoromethyl)phenoxy\]-1- (2,4,6-Trifluorobenzyl)quinazolin-4(1*H*)-One                                                                                                                                                                                −9.6                                              −8.8
  656932       \[(1*R*)-2-\[3-\[methyl-\[1-(naphthalene-2-carbonyl)piperidin-4-yl\]carbamoyl\] naphthalen-2-yl\]-1-naphthalen-1-yl-2-oxoethyl\]phosphonic acid                                                                                                                                                          −9.6                                              --
  N3\*         *N*-\[(5-methylisoxazol-3-yl)carbonyl\]alanyl-l-valyl-n∼1∼-(1*R*,2*Z*)-4-(benzyloxy)- 4-oxo-1-{\[(3*R*)-2-oxopyrrolidin-3-yl\]methyl}but-2-enyl)-l-leucinamide                                                                                                                                           −7.3                                              --
  90176081     (11*S*)-4,9-Dioxo-*N*-\[(2*S*)-1-oxo-3-phenylpropan-2-yl\]-17,22-dioxa-10, 30-diazatetracyclo\[21.2.2.213,16.15,8\]triaconta-1(26),5,7,13,15,23(27), 24,28-octaene-11-carboxamide                                                                                                                        −9.3                                              −9.2
  10Q\*        2-{(2E,4aR,7aR)-7a-\[4-(3-cyanophenyl)thiophen-2-yl\]-2-imino-3-methyl- 4-oxooctahydro-6*H*-pyrrolo\[3,4-d\]pyrimidin-6-yl}pyridine-3-carbonitrile                                                                                                                                                       −9.5                                              --
  25141820     (1*R*,18*R*,22*R*,26*S*,29*S*)-26-cyclopentyl-*N*-\[(1*R*,2*S*)-1-(cyclopropylsulfonylcarbamoyl)-2- ethenylcyclopropyl\]-24,27-dioxo-2,23-dioxa-11,25,28-triazapentacyclo\[26.2.1.03, 12.05,10.018,22\]hentriaconta-3,5,7,9,11-pentaene-29-carboxamide                                                   −9.6                                              --

\*Represents chemical ID from PDB.

Du and company (2007) found that the protease Xa, which is involved in the coagulation pathway described above, is also associated with viral infectivity of the SARS coronavirus (Du et al., [@CIT0026]). The protease factor Xa cleaved the SARS-CoV S protein into two functional units S1 and S2 subunits, which facilitated viral infection. In addition, factor Xa was expressed in ACE2 cells, the host enzyme that the SARS S protein binds to infect human cells (Du et al., [@CIT0026]). The macrocyclic tissue factor--factor VIIa inhibitor is a plausible inhibitor for COVID-19 because it inhibits factor Xa, which may prevent the novel coronavirus from entering its host. The COVID-19 main protease has 97% sequence identity with the SARS-CoV main protease (Zhang et al., [@CIT0067]). Therefore, factor-factor VIIa inhibitors may also block the viral replication in the novel coronavirus. Additionally, the proposed inhibitor has high selectivity towards the novel coronavirus main protease which may help to prevent viral replication.

A MD simulation of the inhibitor (118098670)-protease system shows that the system deviates very little from the x-ray crystal structure ([Figure 1](#F0001){ref-type="fig"}), with root mean square deviation (RMSD) of 3 Å for the protease from crystal structure and 1.5 Å for the inhibitor (118098670) from its starting structure.

![RMSD of inhibitors (red), main protease (black) and protease-inhibitor complex (blue) obtained from 100 ns MD simulation.](TBSD_A_1776158_F0001_C){#F0001}

Both MD ([Table 2](#t0002){ref-type="table"}) and docking studies ([Figure 2](#F0002){ref-type="fig"}) show significant hydrogen bonding, mainly between the inhibitor and the ASP-153 and GLN-110 amino acids in the COVID-19 main protease. In addition, a number of pi interactions were found between benzene rings and HIS-246 and VAL-202 before MD simulation and ILE-249, PRO-293 and PHE-294 after MD simulation ([Figure 2](#F0002){ref-type="fig"} and [Table 3](#t0003){ref-type="table"}). In general, pi interactions play a key role in the stability of ligands in the binding site (Arthur & Uzairu, [@CIT0006]). The key residues in the active site of the COVID-19 main protease are the PHE-294 and ILE-249 residues, with occupancies of 99% and 99%, respectively and it appears the 118098670 inhibitor prefers to bind in the hydrophobic active site of the main protease ([Figure 2A](#F0002){ref-type="fig"}).

![Binding interactions sites of main protease with inhibitors, 118098670 (A), 104161460 (B), 5289412 (C), 1636044(D) and 137349331 (E), obtained from molecular docking.](TBSD_A_1776158_F0002_C){#F0002}

###### 

Average lengths (*r*), angles (θ), and occupancy (*f)* of unique residues in COVID-19 main protease that form intermolecular H-bonds with the five proposed inhibitor complexes from 100 ns MD simulation.[^a^](#TF2){ref-type="table-fn"}^,b^

  Donor/acceptor pair      *f* (%)   *r* (Å)   *θ* (°)
  ------------------------ --------- --------- ---------
  118098670 Inhibitor                          
  GLN-110^NE2^/LIG^O3^     31        3.06      156.7
  ASP-153^OD2^/LIG^N7^     30        2.75      162.6
  ILE-249^HA^/LIG^C19^     27        3.25      158.2
  ASP-248^O^/LIG^N3^       25        3.14      152.9
  ASN-151^CB^/LIG^H33^     18        3.27      154.4
  ASP-245^OD2^/LIG^N4^     16        2.87      156.4
  PHE-294^CB^/LIG^H25^     16        3.31      154.6
  104161460 Inhibitor                          
  GLU-166^N^/LIG^O2^       42        3.03      157.2
  HIS-41^NE2^/LIG^N6^      36        3.09      160.3
  TYR-54^OH^/LIG^N7^       24        3.07      155.4
  ASP-187^O^/LIG^N7^       21        2.98      161.4
  MET-49^O^/LIG^N7^        20        2.95      161.8
  MET-165^CA^/LIG^O2^      15        3.36      145.6
  ARG-188^NH1^/LIG^O2^     13        2.81      162.2
  THR-45^CA^/LIG^O2^       12        3.25      158.6
  SER-46^CA^/LIG^H14^      11        3.26      147.2
  5289412 Inhibitor                            
  VAL-297^HB^/LIG^C26^     32        3.23      152.7
  ASP-153^CG^ /LIG^O6^     27        2.80      161.4
  PHE-294^CA^/LIG^H30^     26        3.28      157.8
  ASP-248^O^/LIG^N3^       25        3.14      152.9
  ILE-249^HA^/LIG^C31^     12        3.31      152.3
  137349331 Inhibitor                          
  THR-169^OG1^/LIG^O3^     26        2.80      163.2
  ASP-197^N^/LIG^O9^       20        3.04      162.5
  163632044 Inhibitor                          
  ASP-187^O^/LIG^N2^       49        2.94      149.0
  GLU-47^CD^ LIG^N4^       43        3.23      147.9
  HIS-41^HB2^ /LIG^C27^    17        3.22      148.1
  GLN-189^NE2^/LIG^O1^     14        3.12      155.1
  MET-165^HB2^/ LIG^C22^   12        3.25      151.3
  GLU-166^N^/LIG^O1^       11        2.95      161.7

^a^Only occupancies (*f*) up to 10% are reported.

^b^3.5 Å hydrogen bond distance is given with respect to the heavy atoms.

###### 

Native contacts of unique residues in COVID-19 main protease with five proposed inhibitors from 100 ns MD simulation.[^a^](#TF4){ref-type="table-fn"}

  1180986670   104161460   5289412   137349331   163632044                                 
  ------------ ----------- --------- ----------- ----------- ---- --------- ---- --------- ----
  PHE-294      99          HIS-41    99          PRO-252     99   THR-169   71   HIS-41    99
  ILE-249      99          ASP-187   99          ILE-249     81   ALA-194   59   THR-25    97
  PRO-293      90          SER-46    96          GLY-251     81   VAL-171   53   MET-49    97
  VAL-297      84          THR-54    96          LEU-253     78                  HIS-164   96
  PRO-252      81          ARG-188   95          LEU-250     78                  MET-165   96
  ASN-151      58          MET-49    95          ASP-258     77                  GLN-189   93
  ASP-153      57          THR-45    91          PRO-293     75                  SER-46    93
  SER-158      56          THR-25    90          ASP-248     74                  GLU-166   87
  GLN-110      54          CYS-44    87          VAL-297     68                  CYS-145   78
  ILE-152      53          GLN-189   86          PHE-294     66                  VAL-42    76
  THR-292      53          LEU-50    85                                          CYS-44    66
  THR-111      53          THR-24    85                                          LEU-27    57
  VAL-104      53          ARG-40    82                                                     
                           GLU-166   70                                                     
                           PRO-52    64                                                     
                           HIS-164   62                                                     
                           ASN-142   61                                                     
                           THR-190   56                                                     
                           MET-165   55                                                     

^a^Only occupancies (*f*) up to 50% are reported.

Our *in silico* approach also finds the factor Xa protease inhibitors, phenyltriazolinones (PubChem ID 104161460) (Quan et al., [@CIT0047]), to have the second highest binding affinity of −10.2 kcal/mol from stand-alone docking calculations and −9.4 kcal/mol from the MD structure of the COVID-19 main protease ([Table 1](#t0001){ref-type="table"}). Experimental data shows that cleavage of the SARS-CoV S protein into functional units increased with the amount of concentration of factor Xa and cleavage of the S protein can be prevented with factor Xa inhibitors (Du et al., [@CIT0026]). Additionally, the high binding affinity of phenyltriazolinone for the COVID-19 main protease may be able to inhibit viral replication of the novel coronavirus. MD simulation shows a number of hydrogen bonds, mainly between the inhibitor and the GLU-166, HIS-41, TYR-54 and ASP-187 residues in the COVID-19 binding pocket ([Table 2](#t0002){ref-type="table"}). Furthermore, a number of pi-interactions are formed with HIS-41, MET-165 and MET-49 before and after MD simulation ([Figure 2](#F0002){ref-type="fig"} and [Table 3](#t0003){ref-type="table"}). This inhibitor is especially important as the inhibitor binds to the active site consisting of a cysteine amino acid and a nearby histidine that cuts polyproteins into functional proteins to facilitate viral replication ([Figure 5B](#F0005){ref-type="fig"}) (Anand et al., [@CIT0005]; Xue et al., [@CIT0065]). In addition, the MD simulation between the inhibitor (104161460)-protease system shows that COVID-19 main protease deviates very little from the original X-ray crystal structure with a RMSD of 3 Å for the protease ([Figure 1](#F0001){ref-type="fig"}).

The third potential protease inhibitor compound, with a binding affinity of −9.4 kcal/mol obtained from standalone docking calculations and −9.7 kcal/mol from the MD structure of the COVID-19 main protease ([Table 1](#t0001){ref-type="table"}), is an endothiapepsin inhibitor (PubChem ID 5289412) (Coates et al., [@CIT0020]). Endothiapepsin is a member of the aspartic proteinase enzymes which are found in HIV retrovirus and they also play major roles in amyloid disease, fungal infections and malaria (Coates et al., [@CIT0020]). The inhibition of these aspartic proteinases with inhibitors have been effective in the treatment of AIDS (dos Santos, [@CIT0024]; Nguyen et al., [@CIT0046]) and these class of inhibitors are targets for many therapeutic drugs (Hartman et al., [@CIT0031]). MD simulation of the inhibitor-protease system indicate that the protease structure remains very similar to that of the x-ray structure (RMSD of 2.3 Å), but the inhibitor reorganizes into the binding pocket of the protease ([Figure 1](#F0001){ref-type="fig"}). MD simulations showed H-bonding between the inhibitor and the VAL-297, ASP-153, PHE-294 and ASP-248 residues ([Table 2](#t0002){ref-type="table"}). In addition, a number of intermolecular interactions were also observed, mainly between the protease and PRO-252, ILE-249, GLY-251, LEU-253 and LEU-250 ([Table 3](#t0003){ref-type="table"}).

A fourth potential protease inhibitor compound that was identified, with a binding affinity of −10 kcal/mol from standalone docking calculations and −9.3 kcal/mol using the MD-derived structure of the COVID-19 main protease ([Table 1](#t0001){ref-type="table"}), is a macrocyclic HCV NS3/4A protease inhibitor (PubChem ID 137349331). The HCV NS3/4A protease in hepatitis C has been a key target for antiviral drugs (McGivern et al., [@CIT0045]). HCV NS3/4A proteases cleaves the hepatitis C polyprotein at four junctions, releasing NS proteins 4A, 4B, 5A and 5B, which is important in viral replication (Bartenschlager et al., [@CIT0009]; Brass et al., [@CIT0014]). Both hepatitis C and the coronavirus contain a positive-stranded genome (Schiering et al., [@CIT0052]) and rely on a similar mechanism to replicate their RNA (Schiering et al., [@CIT0052]; Thiel et al., [@CIT0056]). Furthermore, both COVID-19 and HCV NS3/4A proteases have a double β-barrel fold with similar orientation, regions of structural similarity, and a very similar substrate binding pocket with active site catalytic residues His41 and Cys145 and His57 and Ser139 (Khushboo et al., [@CIT0039]). These similarities make the HCV NS3/4A protease inhibitor a plausible drug candidate to inhibit the COVID-19 main protease to block its viral and transcription function. The interactions between the ligand and ALA-194 and VAL-171 residues are maintained after MD simulation ([Figure 2](#F0002){ref-type="fig"} and [Table 3](#t0003){ref-type="table"}). Furthermore, hydrogen bonding is maintained after MD simulation with the ligand and ASP-197 ([Figure 2](#F0002){ref-type="fig"} and [Table 2](#t0002){ref-type="table"}). A RMSD analysis shows that the RMSD deviates very little from the original X-ray crystal structure (RMSD 3 Å). In addition, the RMSD shows that the ligand seems to reorganize into the binding pocket and displays a similar pattern to the protease ([Figure 1](#F0001){ref-type="fig"}).

Additionally, we find the binding affinity of an allosteric HCV NS5B polymerase thumb pocket 2 protease inhibitor (PubChem ID 163632044 to have −9.6 kcal/mol to the COVID-19 main protease in stand-alone docking calculations and −8.8 kcal/mol using the MD simulation derived structure ([Table 1](#t0001){ref-type="table"}). The class of HCV NS3/4A protease inhibitors have shown to have antiviral activity with hepatitis C patients and a few drugs have already been approved by the FDA (Hinrichsen et al., [@CIT0033]). The designed HCV NS5B polymerase thumb pocket 2 inhibitor created by Hucke et al. (2014) has a greater potency to the most prevalent hepatitis C genotypes (Hucke et al., 2014). Furthermore, the success of HCV protease inhibitors to prevent viral replication in hepatitis C patients could very well translate in the treatment of COVID-19. COVID-19 contains a non-structural protein 12 (nsp12) that catalyzes and synthesizes viral RNA that plays a critical role in viral replication and transcription (Gao et al., [@CIT0028]). The HCV ns5b polymerase, in which the allosteric HCV NS5B polymerase thumb pocket 2 protease inhibitor targets, has been found to have high similarity to nsp12 (Gao et al., [@CIT0028]). Therefore, ns5b polymerase inhibitors are promising drug targets to prevent viral replication of the novel coronavirus. A RMSD calculation of MD simulation finds that the 163632044 inhibitor does not deviate very much from its initial structure after 15 ns, and the protease also does not deviate much from the initial x-ray crystal structure ([Figure 1](#F0001){ref-type="fig"}). The 163632044 inhibitor seems to also be especially important, as it forms native contacts with the His-41 and Cys-145 residues in the COVID-19 main protease active site, with occupancies of 99% and 78%, respectively ([Table 3](#t0003){ref-type="table"} and [Figure 5B](#F0005){ref-type="fig"}). In addition, hydrogen bonding is observed between the inhibitor and HIS-41, ASP-187 and GLU-47 residues ([Table 2](#t0002){ref-type="table"}). The His-41 and Cys-145 residues are especially important as they make up the catalytic dyad in the COVID-19 main protease and cut polyproteins into functional proteins to facilitate viral replication. Thus, their inhibition may be especially important in the development of antiviral drugs that target COVID-19.

To further assess the stability and dynamics of the top three proposed protease-inhibitor complexes, the radius of gyration (Rg), solvent accessible surface area (SASA), and a principal component analysis (PCA) were calculated and compared to the main protease crystal structure obtained from PDB 6LU7. Eigenvectors is a PCA method to determine the motion of the protein-inhibitor complexes along two principal components. [Figure 3](#F0003){ref-type="fig"} shows the eigenvector for a 100 ns simulation with a 2ps time step.

![Projection of motion along first two principal eigenvectors for Cα atoms of main protease (black), protease-118098670 complex (red), protease-104161460 complex (green), protease-5289412 complex (blue).](TBSD_A_1776158_F0003_C){#F0003}

Overall, the distribution of motion is very similar for the three proposed inhibitor-protease systems compared to the Mpro. The internal motion of the protease-inhibitor systems seems to be defined along the first eigenvector ([Figure 3](#F0003){ref-type="fig"}). The radius of gyration and solvent accessible surface area analysis also agree with the PCA calculation ([Figure 4](#F0004){ref-type="fig"}).

![Radius of gyration (Rg) and solvent accessible surface area (SASA) of Cα atoms of main protease (black), protease-118098670 complex (red), protease-104161460 complex (green), protease-5289412 complex (blue).](TBSD_A_1776158_F0004_C){#F0004}

The radius of gyration (Rg) of all protease-inhibitor complexes are found very similar to the Mpro crystal structure with Rg values between 21.75 and 22.75 Å. In addition, the solvent accessible surface area analysis shows that all three proposed inhibitor-protease systems are relatively similar and the values for the Mpro overlap well with the proposed protease-inhibitor systems.

Furthermore, the binding affinity of lopinavir, one of the HIV-protease inhibitors, and hydroxychloroquine, a drug to treat malaria, with the COVID-19 main protease are found to be −8.2 and −6.3 kcal/mol, respectively. The binding site for lopinavir is found to be similar to the 118098670, 137349331 and 5289412 inhibitors. The 118098670 and 5289412 inhibitors share the same native contacts with ILE-249, VAL-297 and PHE-294 in the main protease. Furthermore, both the 118098670 and 5289412 inhibitors form hydrogen bonds with the ASP-153, PHE-294, ASP-248 and the ILE-249 residues in the main protease. Interestingly, hydroxychloroquine's binding site is found to be similar to the 104161460 and 163632044 inhibitors (see supporting info). Early data suggests that hydroxychloroquine may be effective in the treatment of COVID-19 by preventing symptoms from worsening and improving recovery times (Z. Chen et al., [@CIT0017]). The early data from hydroxychloroquine may further exemplify the importance of targeting the catalytic dyad of His-41 and Cys-145 in the COVID-19 active site. Since hydroxychloroquine and the 104161460 and 163632044 inhibitors both interact with His-41 and Cys-145 residues in the active site of the COVID-19 main protease, they may very well be potential drug candidates to inhibit the viral replication abilities of the COVID-19 main protease. The catalytic dyad active site of the 104161460 and 163632044 inhibitors in the COVID-19 main protease are shown in [Figure 5B](#F0005){ref-type="fig"}. In addition, the 104161460 and 163632044 inhibitors share many of the same contacts with SER-46, MET-49, GLN-189, GLU-166, HIS-164 and MET-65. Hydrogen bonding is shared between residues ASP-187, HIS-41 and MET-165 and the main protease. The His and Cys residues appear in a mostly hydrophilic binding pocket and it seems that both hydroxychloroquine and the 104161460 and 163632044 inhibitors prefer this hydrophilic active site ([Figure 5B](#F0005){ref-type="fig"}).

![Binding modes showing (A) 118098670 inhibitor interacts with the active site consisting of Phe-294 and Ile-249 residues of main protease and (B) the 104161460 and 163632044 inhibitors interacts with the catalytic dyad His-41 and Cys-145 residues of main protease. Blue color represents the hydrophilic residues, while orange-red color represents hydrophobic residues.](TBSD_A_1776158_F0005_C){#F0005}

Next, the theoretical dissociation calculations, *K*~d~, obtained from the MD derived crystal structures were compared to the experimental dissociation constant, *K*~d~, values of similar protease-inhibitor systems ([Table 4](#t0004){ref-type="table"}). The theoretical *K*~d~ values are calculated from MD-derived binding free energy (Δ*G*) values as shown in [Table 1](#t0001){ref-type="table"} using the equation Δ*G*=*RT*ln *K*~d~. The five proposed inhibitors, 118098670, 5289412, 104161460, 137349331 and 163632044, have theoretical dissociation constants (*K*~d~) of 5.18 × 10^−8,^ 8.48 × 10^−8,^ 1.40 × 10^−7,^ 1.66 × 10^−7,^ and 3.84 × 10^−7^ M, respectively ([Table 4](#t0004){ref-type="table"}). Experimentally *K*~d~ values were determined for similar protease-inhibitor systems. Theoretical *K*~d~ values of five proposed inhibitors to the COVID-19 main protease are found to agree very well with the experimental *K*~d~ values for similar protease-inhibitor systems. The 118098670 inhibitor is found to have an experimental *K*~d~ value of 1.60 × 10^−9^ M against some serine proteases FIXa, FXa, thrombin, and trypsin (Ladziata et al., [@CIT0041]), which agree with the theoretical *K*~d~ value, 5.18 × 10^−8^ M. In addition, the 5289412 inhibitor is found to have an experimental *K*~d~ of 4.00 × 10^−9^ M against saccharopepsin, an aspartic protease (Cronin et al., [@CIT0021]). This binding affinity is also in agreement with the theoretical dissociation constant, 8.48 × 10^−8^ M. Furthermore, the 104161460 inhibitor has an experimental *K*~d~ of 1.90 × 10^−10^ M against factor Xa proteases (Quan et al., [@CIT0047]), which also agrees with our theoretical calculations ([Table 4](#t0004){ref-type="table"}).

###### 

Theoretical and experimental dissociation constants for the five proposed inhibitors.

  PubChem ID   Theoretical Kd (M)   Experimental Kd (M)
  ------------ -------------------- --------------------------------
  118098670    5.18 × 10^−8^        1.60 × 10^−9^
  5289412      8.48 × 10^−8^        4.00 × 10^−9^
  104161460    1.40 × 10^−7^        1.90 × 10^−10^
  137349331    1.66 × 10^−7^        1.00 × 10^−10^, 4.60 × 10^−10^
  163632044    3.84 × 10^-7^        6.00 × 10^−8^

The use of FDA approved drugs or already existing experimental drugs against COVID-19 can dramatically improve the time required to provide therapeutic benefit against the novel coronavirus. The 137349331 inhibitor identified from molecular docking is similar to the hepatitis C macrocyclic NS3/4A inhibitors Vaniprevir and Danoprevir, which have already been approved for human use. Danoprevir, in particular, is already being used in clinical trials in China to treat COVID-19 patients (H. Chen et al., [@CIT0017]). The experimental binding affinity (*K*~d~) of Vaniprevir and Danoprevir against the HCV NS3/4A serine protease is found to be 4.60 × 10^−10^ and 1.00 × 10^−10^ M, respectively (Ali et al., [@CIT0003]). These values are in agreement with the *K~d~* values found from our theoretical calculations ([Table 4](#t0004){ref-type="table"}). Furthermore, the proposed 163632044 inhibitor is very similar to Gilead's hepatitis C drug Sofosbuvir that is currently being investigated as a potential drug for COVID-19. Sofosbuvir has an experimental *K*~d~ value of 6.00 × 10^−8^ M against the NS5B polymerase of the hepatitis C virus ('Sovaldi (sofosbuvir),' 2015). This experimental *K*~d~ value is very similar to that obtained from calculation of the 163632044 HCV NS5B polymerase inhibitor against the COVID-19 main protease, with a *K*~d~ value of 3.84 × 10^−7^ M.

Moreover, the calculated dissociation constants of the five proposed COVID-19 protease inhibitors were plotted against the experimental dissociation constant values (see supporting info). The correlation coefficient *R*^2^ is 0.81, indicating that there is a substantial correlation between our theoretical dissociation constant values and experimental dissociation constant values (see supporting info.)

Toxicity is a major issue in drug development. Most drug candidates fail in clinical trials due to toxicity that the body cannot tolerate. ProTox-II (Banerjee et al., [@CIT0008]) was used to check the toxicity of the five proposed inhibitors, namely 118098670, 5289412, 104161460, 137349331 and 163632044, found in this study, to assess the safety profile of these chemical compounds. ProTox-II (Banerjee et al., [@CIT0008]) shows that all these inhibitors may be tolerable by the body, since the hepatotoxicity profile of these compounds were found inactive with probabilities of 54%, 80%, 55%, 50% and 55%, respectively.

Conclusions {#s0004}
===========

To summarize, this study identified the best inhibitor that binds with the main protease of COVID-19 to be the macrocyclic tissue factor-factor VIIa inhibitor (PubChem ID: 118098670). Both molecular docking and MD derived binding affinities were found to be −10.6 and −10.0 kcal/mol, respectively. In some people, the increased inflammation caused by the COVID-19 virus had led to increased clotting (Willyard, [@CIT0062]). The TF-FVIIa inhibitors are known to prevent the coagulation of blood and have antiviral activity as shown in the case of SARS coronavirus (Du et al., [@CIT0026]). Also, TF-VIIa coagulation cascade inhibitors are viewed as promising treatments for malaria, (Kendrick et al., [@CIT0036]; Ruf, [@CIT0051]), as studies indicate increased coagulation activity in malaria (Gérardin et al., [@CIT0030]; Ladhani et al., [@CIT0040]). Furthermore, this study finds the phenyltriazolinones (PubChem ID: 104161460) and allosteric HCV NS5B polymerase thumb pocket 2 (PubChem ID: 163632044) inhibitors to be plausible inhibitors for the inhibition of the COVID-19 main protease, as these inhibitors interact with the His-41 and Cys-145 catalytic dyad in the COVID-19 main protease that has been found to be especially important in viral replication (Zhu et al., [@CIT0068]). This study also found the endothiapepsin (PubChem ID: 5289412) and macrocyclic HCV NS3/4A (PubChem ID: 137349331) protease inhibitors to be plausible inhibitors of the COVID-19 main protease, and clinically they have also shown great antiviral activity. The results obtained from our theoretical dissociation constant values of five proposed inhibitors to the COVID-19 main protease agree very well with the experimental values for similar protease-inhibitor systems. Future studies may employ more computationally intensive approaches such as molecular mechanics/generalized born surface area (MM/GBSA) to predict binding free energy of coronavirus inhibitors. In addition, docking studies and MD may also be used to target the coronavirus spike protein to prevent it from entering ACE2 host cells.
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